Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1969 1
1971 3
1972 4
1973 5
1974 5
1975 4
1976 4
1977 5
1978 5
1979 4
1980 2
1981 3
1982 2
1983 7
1984 3
1985 5
1986 2
1987 2
1989 4
1990 6
1991 2
1992 4
1993 9
1994 4
1995 2
1996 8
1997 7
1998 8
1999 9
2000 8
2001 6
2002 5
2003 9
2004 4
2005 1
2006 8
2007 10
2008 2
2009 2
2010 3
2011 2
2012 5
2013 4
2014 4
2015 7
2016 6
2017 9
2018 6
2019 9
2020 7
2021 6
2022 5
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

248 results

Results by year

Filters applied: . Clear all
Page 1
Lymphoplasmacytic Lymphoma and Marginal Zone Lymphoma.
Juárez-Salcedo LM, Castillo JJ. Juárez-Salcedo LM, et al. Hematol Oncol Clin North Am. 2019 Aug;33(4):639-656. doi: 10.1016/j.hoc.2019.03.004. Epub 2019 Apr 30. Hematol Oncol Clin North Am. 2019. PMID: 31229160 Review.
Lymphoplasmacytic lymphoma (LPL) and marginal zone lymphoma (MZL) are indolent subtypes of non-Hodgkin lymphoma. ...
Lymphoplasmacytic lymphoma (LPL) and marginal zone lymphoma (MZL) are indolent subtypes of non-Hodgkin lymphoma. …
Marginal Zone Lymphoma: State-of-the-Art Treatment.
Sindel A, Al-Juhaishi T, Yazbeck V. Sindel A, et al. Curr Treat Options Oncol. 2019 Dec 5;20(12):90. doi: 10.1007/s11864-019-0687-5. Curr Treat Options Oncol. 2019. PMID: 31807935 Review.
Despite being the second most common indolent non-Hodgkin's lymphoma (iNHL), marginal zone lymphoma (MZL) remains largely understudied, and given its underlying disease heterogeneity, it is challenging to define a single treatment approach for these pa …
Despite being the second most common indolent non-Hodgkin's lymphoma (iNHL), marginal zone lymphoma (MZL) remains large …
Epstein-Barr virus and its association with disease - a review of relevance to general practice.
Fugl A, Andersen CL. Fugl A, et al. BMC Fam Pract. 2019 May 14;20(1):62. doi: 10.1186/s12875-019-0954-3. BMC Fam Pract. 2019. PMID: 31088382 Free PMC article. Review.
BACKGROUND: General practitioners encounter the vast majority of patients with Epstein-Barr virus-related disease, i.e. infectious mononucleosis in children and adolescents. ...Association between lymphoproliferative cancers, especially Hodgkin lymphoma and B …
BACKGROUND: General practitioners encounter the vast majority of patients with Epstein-Barr virus-related disease, i.e. infectious mo …
Current Treatments in Marginal Zone Lymphoma.
Alderuccio JP, Kahl BS. Alderuccio JP, et al. Oncology (Williston Park). 2022 Apr 6;36(4):206-215. doi: 10.46883/2022.25920956. Oncology (Williston Park). 2022. PMID: 35436062 Free article. Review.
Marginal zone lymphoma (MZL) is a heterogenous group of indolent non-Hodgkin lymphomas (NHLs). Three subtypes are recognized based on the site of involvement: extranodal MZL, splenic MZL, and nodal MZL. MZL represents 7% of all mature NHLs that exhibit geogra …
Marginal zone lymphoma (MZL) is a heterogenous group of indolent non-Hodgkin lymphomas (NHLs). Three subtypes are recognized b …
Histiocytic Sarcoma.
Tocut M, Vaknine H, Potachenko P, Elias S, Zandman-Goddard G. Tocut M, et al. Isr Med Assoc J. 2020 Oct;22(10):645-647. Isr Med Assoc J. 2020. PMID: 33070490 Free article. Review.
HS can occur in isolation or in association with other hematological neoplasms such as non-Hodgkin lymphoma (NHL), myelodysplasia, or acute leukemia. Clinically, HS can affect lymph nodes, gastrointestinal tract, skin, bone marrow, and spleen as well as the c …
HS can occur in isolation or in association with other hematological neoplasms such as non-Hodgkin lymphoma (NHL), myelodyspla …
BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphoma.
Eyre TA, Shah NN, Dreyling M, Jurczak W, Wang Y, Cheah CY, Song Y, Gandhi M, Chay C, Sharman J, Andorsky DJ, Messersmith HM, Ruppert AS, Muthig VA, Ito R, Wang ML. Eyre TA, et al. Future Oncol. 2022 Nov;18(36):3961-3969. doi: 10.2217/fon-2022-0976. Epub 2022 Nov 15. Future Oncol. 2022. PMID: 36377973 Free article. Review.
Treatment with covalent Bruton tyrosine kinase inhibitors (BTKi) represents an important advance in the management of relapsed or refractory mantle cell lymphoma, but these treatments are not curative and many patients ultimately relapse. ...This phase III, head-to-head, r …
Treatment with covalent Bruton tyrosine kinase inhibitors (BTKi) represents an important advance in the management of relapsed or refractory …
Hodgkin lymphoma.
Gobbi PG, Ferreri AJ, Ponzoni M, Levis A. Gobbi PG, et al. Crit Rev Oncol Hematol. 2013 Feb;85(2):216-37. doi: 10.1016/j.critrevonc.2012.07.002. Epub 2012 Aug 4. Crit Rev Oncol Hematol. 2013. PMID: 22867814 Review.
Hodgkin lymphoma (HL) is a curable malignancy which shows a bimodal curve in incidence in economically developed countries; there is a putative association with Epstein-Barr virus. ...Splenic involvement is usually concomitant with hepatic disease and
Hodgkin lymphoma (HL) is a curable malignancy which shows a bimodal curve in incidence in economically developed countries; th
Oxaliplatin-related thrombocytopenia.
Jardim DL, Rodrigues CA, Novis YAS, Rocha VG, Hoff PM. Jardim DL, et al. Ann Oncol. 2012 Aug;23(8):1937-1942. doi: 10.1093/annonc/mds074. Epub 2012 Apr 25. Ann Oncol. 2012. PMID: 22534771 Free article. Review.
Most of the experience with the clinical use of this drug is derived from colorectal cancer but it is also used in other tumor types such as ovary, breast, liver and non-Hodgkin's lymphoma. Thrombocytopenia is a frequent toxicity seen during oxaliplatin treatment, o …
Most of the experience with the clinical use of this drug is derived from colorectal cancer but it is also used in other tumor types such as …
Splenic marginal zone lymphoma: a case report and literature review.
Zhang S, Xuan Z, Zhang L, Lu J, Song P, Zheng S. Zhang S, et al. World J Surg Oncol. 2020 Oct 1;18(1):259. doi: 10.1186/s12957-020-02030-3. World J Surg Oncol. 2020. PMID: 33004051 Free PMC article. Review.
BACKGROUND: Splenic marginal zone lymphoma (SMZL) is a rare non-Hodgkin lymphoma, and much little is known about its clinical characteristics and management strategies. ...Patients with SMZL are generally associated with favorable prognosis. Combining …
BACKGROUND: Splenic marginal zone lymphoma (SMZL) is a rare non-Hodgkin lymphoma, and much little is known about …
B-cell neoplasms and Hodgkin lymphoma in the spleen.
Geyer JT, Prakash S, Orazi A. Geyer JT, et al. Semin Diagn Pathol. 2021 Mar;38(2):125-134. doi: 10.1053/j.semdp.2020.08.002. Epub 2020 Aug 10. Semin Diagn Pathol. 2021. PMID: 32839024 Review.
B-cell lymphoma of spleen may be primary (most commonly splenic diffuse large B-cell lymphoma) or secondary (typically low-grade non-Hodgkin lymphoma). ...Splenectomy is the ideal specimen for a multiparametric integrative diagnosis of …
B-cell lymphoma of spleen may be primary (most commonly splenic diffuse large B-cell lymphoma) or secondary (typ …
248 results